Evaluation of azacitidine in patients with transplant-ineligible myelodysplastic syndromes and acute myeloid leukemia with myelodysplasia-related changes in a Japanese clinical setting

Patients with high-risk myelodysplastic syndromes (MDS) treated with azacitidine (AZA) have exhibited improved overall survival. However, information on AZA in real-world settings is limited. The present study retrospectively analyzed 85 patients with MDS treated with AZA. Complete response was achi...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakaya, Aya, Fujita, Shinya, Satake, Atsushi, Nakanishi, Takahisa, Azuma, Yoshiko, Tsubokura, Yukie, Saito, Ryo, Konishi, Akiko, Hotta, Masaaki, Yoshimura, Hideaki, Ishii, Kazuyoshi, Ito, Tomoki, Nomura, Shosaku
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6956411/
https://www.ncbi.nlm.nih.gov/pubmed/31966063
http://dx.doi.org/10.3892/ol.2019.11225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6956411/
https://www.ncbi.nlm.nih.gov/pubmed/31966063
http://dx.doi.org/10.3892/ol.2019.11225

Ejemplares similares